Tasly: As of the first quarter, the company's drug sales revenue in the field of liver disease treatment increased by 33%, and related drugs are currently mainly sold in China.


Full Data

?
UNLOCK DATA

Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets


Join Now!

Need this critical market data?

Access thousands of market events, data points, and news articles!


Already have an account?
Login




Related Data